On Thursday, Shares of Priceline Group Inc (NASDAQ:PCLN), lost -0.20% to $1,240.37.
Priceline Group, declared the acquisition of AS Digital, a leading provider of restaurant table and reservation administration solutions. Based in Australia, AS Digital will expand The Priceline Group’s global footprint in the digital restaurant reservation booking business, following the Group’s acquisition of OpenTable in 2014. AS Digital will roll into the OpenTable brand within The Priceline Group, and serve to accelerate OpenTable’s entry into the Australian market and expand its operations in Japan and across the Asia Pacific region. Terms of the deal have not been revealed.
AS Digital operates ResPAK, a comprehensive table reservation and administration software solution with a robust feature set that assists thousands of restaurants in over 40 countries manage their front-of-house operations seamlessly and efficiently. In addition, AS Digital powers mobile apps, widgets and websites under the brand bookarestaurant.com that assist consumers find and book restaurants all over the world.
The Priceline Group Inc. provides online travel and travel related reservation and search services. The company operates Booking.com, which provides online accommodation reservation services; and priceline.com that offers hotel, rental car, and airline ticket reservations services, in addition to vacation packages and cruises through its Name Your Own Price and Express Deals travel services.
Shares of Acorda Therapeutics Inc (NASDAQ:ACOR), declined -2.15% to $31.86, during its last trading session.
Acorda Therapeutics declared that Michael Rogers, Chief Financial Officer, will present at the Baird 2015 Healthcare Conference in New York on Wednesday, September 9 at 2:00pm.
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the administration of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the administration of neuropathic pain associated with post-herpetic neuralgia.
At the end of Thursday’s trade, Shares of POZEN Inc. (NASDAQ:POZN), lost -5.08% to $ 8.60.
POZEN Inc., declared results for the second quarter ended June 30, 2015. The Company highlighted important corporate, commercial, and regulatory updates from the quarter.
Total revenues resulting from VIMOVO® royalties for the three month period ended June 30, 2015, were $5.2 million, contrast to total revenues of $7.4 million in the second quarter of 2014 that comprised $5.4 million of royalties and $2.0 million of amortization of the upfront fee for licensing of YOSPRALA, representing a decrease of thirty percent. Total revenues for the second quarter of 2015 raised 18% from the first quarter of 2015, reflecting royalty improvements in both US and non-US markets.
As predictable, operating expenses for the second quarter of 2015 raised due to certain transition and transactional costs and totaled $20.5 million, contrast to $4.4 million for the comparable period in 2014. The improvement in operating expenses in the second quarter of 2015 was primarily a result of transaction-related costs of $5.2 million; one time severance costs for the former CEO of $7.6 million; staff retention costs of $0.8 million; new hire costs of $0.7 million, YOSPRALA-related pre-commercialization costs of $1.1 million, patent litigation costs of $0.4 million, and $0.3 million other departmental costs.
POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its principal PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have accomplished clinical development in the United States.
Finally, Ubiquiti Networks Inc (NASDAQ:UBNT), ended its last trade with 1.96% gain, and closed at $36.40.
Ubiquiti Networks, declared UniFi(R) AC, 4 new access points and a redesigned UniFi Controller featuring advanced technology for enterprise, hospitality, and education markets. Starting at $89 MSRP, UniFi AC is Ubiquiti’s latest step in democratizing powerful enterprise Wi-Fi networks for the world.
The new UniFi AC access points (APs) feature up to 5x faster speeds than 802.11n APs to support high-density Wi-Fi networks. The APs feature MIMO, 802.11ac, dual-concurrent radio technology, advanced RF, new industrial design for versatile and seamless wall/ceiling mounting, and rapid deployment using your iOS or Android-based mobile app — no controller needed.
The newly redesigned UniFi Controller optimizes RF performance with several powerful new features: Spectral analysis collects feedback on full 5 GHz and 2.4 GHz channel interference, band steering pushes clients to faster interference-free 5 GHz channels, and airtime fairness minimizes problem-client effects on system performance by limiting their airtime access.
Ubiquiti Networks, Inc. provides networking products and solutions for service providers and enterprises worldwide. Its service provider product platforms provide carrier-class network infrastructure for fixed wireless broadband, wireless backhaul systems, and routing; and enterprise product platforms offer wireless LAN infrastructure, video surveillance products, VOIP phones, switches, and machine-to-machine communication components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
